

Kimberly C Banks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3013058/publications.pdf>

Version: 2024-02-01

13
papers

1,793
citations

686830

13
h-index

1058022

14
g-index

15
all docs

15
docs citations

15
times ranked

3521
citing authors

#	ARTICLE	IF	CITATIONS
1	A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study. <i>Clinical Cancer Research</i> , 2021, 27, 1631-1640.	3.2	70
2	Genomic profile of advanced breast cancer in circulating tumour DNA. <i>Nature Communications</i> , 2021, 12, 2423.	5.8	54
3	Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases. <i>Cancer</i> , 2020, 126, 3219-3228.	2.0	106
4	Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1611-1623.	0.5	43
5	Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2354-2361.	3.2	70
6	Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. <i>Clinical Cancer Research</i> , 2019, 25, 6107-6118.	3.2	54
7	Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. <i>Clinical Cancer Research</i> , 2019, 25, 7035-7045.	3.2	152
8	Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2018, 23, 586-593.	1.9	75
9	Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies. <i>Clinical Cancer Research</i> , 2018, 24, 3539-3549.	3.2	307
10	The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 3528-3538.	3.2	288
11	Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. <i>Cancer Research</i> , 2017, 77, 5419-5427.	0.4	92
12	Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. <i>Nature Genetics</i> , 2017, 49, 1693-1704.	9.4	423
13	Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. <i>Oncotarget</i> , 2016, 7, 66880-66891.	0.8	54